Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT02847650
Other study ID # B7601011
Secondary ID 2016-001575-71
Status Terminated
Phase Phase 2
First received
Last updated
Start date October 17, 2016
Est. completion date January 29, 2018

Study information

Verified date October 2020
Source Pfizer
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study is to evaluate the efficacy, safety and tolerability of PF-06649751 in Parkinson's disease patients at early stage of the disease.


Description:

The B7601011 study has a randomized, double-blind, placebo-controlled parallel group design. Approximately 88 subjects will be randomized to 2 treatment groups. Each subject will participate in the study for approximately 23 weeks including a 30 day screening period, 15 week double blind treatment period, and an approximately 28 day follow-up period.


Recruitment information / eligibility

Status Terminated
Enrollment 57
Est. completion date January 29, 2018
Est. primary completion date January 29, 2018
Accepts healthy volunteers No
Gender All
Age group 45 Years to 80 Years
Eligibility Inclusion Criteria: - Females of non-childbearing potential and/or male subjects - Clinical diagnosis of Parkinson's disease. - Parkinson's Disease Hoehn & Yahr Stage I-III inclusive - Treatment naïve or history of prior incidental treatment with dopaminergic agents for no more than 28 days - Able to refrain from any Parkinson's disease medication not permitted by the protocol. Exclusion Criteria: - History or presence of atypical Parkinsonian syndrome. - Severe acute or chronic medical or psychiatric condition or cognitive impairment or laboratory abnormality. - Any condition possibly affecting drug absorption. - Participation in other studies involving investigational drug(s), or treatment with any investigational drug within 30 days.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Placebo

PF-06649751


Locations

Country Name City State
France Hopital Henri Mondor Créteil
France Hôpital Henri Mondor CRÉTEIL Cedex
France CHU de Grenoble Alpes Grenoble
France CHU Grenoble Alpes La Tronche
France Hospital de La Timone Marseille
France Hospital La Timone Marseille
France Hopital Pitie Salpetriere Paris
France Hopital Pitie-Salpetriere Paris
Germany St. Josef Hospital GmbH Bochum Nordrhein-westfalen
Germany Praxis Oehlwein Outpatient clinic for PD, DBS, Movement Disorders Gera
Germany Klinik Haag i. OB Haag I. OB
Germany Paracelsus-Elena-Klinik Kassel Kassel
Germany Universitätsklinikum Gießen und Marburg GmbH Marburg
Germany University hospital Tuebingen Tuebingen
Germany Universitaetsklinik Ulm Ulm
Israel Edith Wolfson Medical Center Holon
Israel Pharmacy, Edith Wolfson Medical Center Holon
United States Asheville Neurology Specialists PA Asheville North Carolina
United States Atlanta Center for Medical Research Atlanta Georgia
United States Parkinson's Disease and Movement Disorders Center of Boca Raton Boca Raton Florida
United States Brigham and Women's Hospital Boston Massachusetts
United States Massachusetts General Hospital Boston Massachusetts
United States Rush University Medical Center Chicago Illinois
United States Cleveland Clinic Cleveland Ohio
United States AS Clinical Research Consultants of North Texas, PLLC Greenville Texas
United States Baylor College of Medicine Houston Texas
United States University of Kansas Medical Center Kansas City Kansas
United States University of Miami Miami Florida
United States St Joseph's Hospital and Medical Center, Barrow Neurology Clinics Phoenix Arizona
United States St. Joseph's Hospital and Medical Center Phoenix Arizona
United States University of South Florida Tampa Florida
United States University of South Florida Carol and Frank Morsani Center for Advanced Health Care Tampa Florida
United States University of South Florida Faculty Office Building Tampa Florida
United States University of South Florida Parkinson's Disease and Movement Disorders Center Tampa Florida
United States University of Toledo Toledo Ohio
United States University of Toledo, Gardner-McMaster Parkinson Center Toledo Ohio
United States Sentara Neurology Specialists Virginia Beach Virginia

Sponsors (1)

Lead Sponsor Collaborator
Pfizer

Countries where clinical trial is conducted

United States,  France,  Germany,  Israel, 

Outcome

Type Measure Description Time frame Safety issue
Primary Change From Baseline in the Movement Disorder Society - Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Part III Total Score at Week 15 MDS-UPDRS Part III was used to assess the motor signs of Parkinson's disease. It was comprised of 33 sub-scores based on 18 items, several with right, left or other body distribution scores. Each question was anchored with 5 responses that were linked to commonly accepted clinical terms: 0=normal, 1=slight, 2=mild, 3=moderate, and 4=severe. The MDS-UPDRS Part III total score range is 0-132. Higher score indicates more severe motor signs of Parkinson's disease. A negative change from baseline represents an improvement in motor function. Baseline (Day -1/randomization), Week 15
Secondary Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs) An AE was any untoward medical occurrence in a participant who received study treatment without regard to possibility of causal relationship. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; life-threatening (immediate risk of death); initial or prolonged inpatient hospitalization; persistent or significant disability/incapacity; congenital anomaly/birth defect. Treatment-emergent AEs were those with initial onset or increasing in severity after the first dose of study treatment. From first dose of study treatment up to 28 days after last dose (up to Day 133)
Secondary Number of Participants With Laboratory Test Abnormalities (Without Regard to Baseline Abnormality) Following safety laboratory parameters were assessed against pre-defined abnormality criteria: hematology (hemoglobin, hematocrit, red blood cell count, mean corpuscular volume, mean corpuscular hemoglobin, mean corpuscular hemoglobin concentration, platelet count, white blood cell count, absolute total neutrophils, absolute eosinophils, absolute basophils, absolute monocytes, and absolute lymphocytes); chemistry (blood urea nitrogen/urea and creatinine, glucose , calcium, sodium, potassium, chloride, total bicarbonate, aspartate aminotransferase [AST], alanine aminotransferase [ALT], total bilirubin, alkaline phosphatase, uric acid, albumin, total protein); urinalysis (pH, qualitative glucose, qualitative protein, qualitative blood, ketones, nitrites, leukocyte esterase, urine bilirubin, urobilinogen, urine creatinine, microscopy, and specific gravity). Baseline (Day -1/randomization) up to Day 119 follow-up visit
Secondary Number of Participants With Vital Signs Data Meeting Categorical Summarization and Orthostatic Hypotension Criteria Vital signs categorical summarization criteria: 1) supine and standing systolic blood pressure (SBP) <90 millimeters of mercury (mmHg); 2) supine and standing diastolic blood pressure (DBP) <50 mmHg; 3) supine pulse rate <40 or >120 beats per minute (bpm); 4) standing pulse rate <40 or >140 bpm; 5) maximum change from baseline (increase or decrease) in supine and standing DBP greater than or equal to (>=) 20 mmHg; 6) maximum change from baseline (increase or decrease) in supine and standing SBP >=30 mmHg. Orthostatic hypotension criterion was defined as a decrease of >=20 mmHg for SBP or >=10 mmHg for DBP 2 minutes after standing from a supine position. Baseline (Day -1/randomization) up to Day 119 follow-up visit
Secondary Number of Participants Meeting the Categorical Summarization Criteria for Electrocardiogram (ECG) Parameters ECG categorical summarization criteria: 1) QRS duration (time from ECG Q wave to the end of the S wave corresponding to ventricle depolarization): >=140 milliseconds (msec), >=50% increase from baseline; 2) PR interval (the interval between the start of the P wave and the start of the QRS complex, corresponding to the time between the onset of the atrial depolarization and onset of ventricular depolarization): >=300 msec, >=25% increase when baseline is > 200 msec or >=50% increase when baseline is less than or equal to (<=) 200 msec; 3) QT interval (time from ECG Q wave to the end of the T wave corresponding to electrical systole): absolute value of >=500 msec; 4) QTcF interval (QT corrected for heart rate using Fridericia's formula): absolute value of 450 to <480 msec, 480 to <500 msec, >=500 msec; an increase from baseline of 30 to <60 msec or >=60 msec. Baseline (Day -1/randomization) up to Day 119 follow-up visit
Secondary Number of Participants With Worsening and New Onset Suicidality as Assessed by Columbia Suicide Severity Rating Scale (C-SSRS) The C-SSRS is an interview based rating scale to systematically assess suicidal ideation and suicidal behavior. C-SSRS responses were mapped to the Columbia Classification Algorithm of Suicide Assessment (C-CASA). Participants with new onset suicidality were those without suicidal ideation and behavior at baseline and reported any suicidal behavior or ideation post-baseline as assessed by C-CASA code mapped from C-SSRS data. Participants with worsening suicidality were those who moved to a lower numbered C-CASA category than was reported at baseline. Baseline (Day -1/randomization) up to Day 119 follow-up visit
Secondary Change From Baseline in Questionnaire for Impulsive-Compulsive Disorders in Parkinson's Disease - Rating Scale (QUIP-RS) Total Score at Days 35, 63, and 105 The QUIP-RS has 4 primary questions pertaining to commonly reported thoughts, urges/desires, and behaviors associated with impulsive-compulsive disorder , each applied to the 4 impulsive-compulsive disorders (compulsive gambling, buying, eating, and sexual behavior) and 3 related disorders (medication use, punding, and hobbyism). Each question is anchored with the following 5 responses: Never (0), Rarely (1), Sometimes (2), Often (3), and Very Often (4). The scoring range for each item (ie, disorder) is 0-16. The QUIP-RS total score range is 0-64. Higher score indicates a greater level of the impulsive compulsive disorder. Baseline (Day -1 or randomization); Days 35, 63, 105
Secondary Total Physician Withdrawal Checklist (PWC-20) Score The PWC-20 is a 20-item reliable and sensitive instrument for the assessment of benzodiazepine-like discontinuation symptoms. The total PWC-20 score is the sum of 20 item scores and ranges between 0 and 60. The higher score indicates more frequent/severe symptoms. Day 119
See also
  Status Clinical Trial Phase
Completed NCT05415774 - Combined Deep Brain Stimulation in Parkinson's Disease N/A
Recruiting NCT04691661 - Safety, Tolerability, Pharmacokinetics and Efficacy Study of Radotinib in Parkinson's Disease Phase 2
Active, not recruiting NCT05754086 - A Multidimensional Study on Articulation Deficits in Parkinsons Disease
Completed NCT04045925 - Feasibility Study of the Taïso Practice in Parkinson's Disease N/A
Recruiting NCT04194762 - PARK-FIT. Treadmill vs Cycling in Parkinson´s Disease. Definition of the Most Effective Model in Gait Reeducation N/A
Completed NCT02705755 - TD-9855 Phase 2 in Neurogenic Orthostatic Hypotension (nOH) Phase 2
Terminated NCT03052712 - Validation and Standardization of a Battery Evaluation of the Socio-emotional Functions in Various Neurological Pathologies N/A
Recruiting NCT05830253 - Free-living Monitoring of Parkinson's Disease Using Smart Objects
Recruiting NCT03272230 - Assessment of Apathy in a Real-life Situation, With a Video and Sensors-based System N/A
Recruiting NCT06139965 - Validity and Reliability of the Turkish Version of the Comprehensive Coordination Scale in Parkinson's Patients
Completed NCT04580849 - Telerehabilitation Using a Dance Intervention in People With Parkinson's Disease N/A
Completed NCT03980418 - Evaluation of a Semiconductor Camera for the DaTSCAN™ Exam N/A
Completed NCT04477161 - Effect of Ketone Esters in Parkinson's Disease N/A
Recruiting NCT04788693 - Effects of Gait Rehabilitation With Motor Imagery in People With Parkinson's Disease N/A
Completed NCT04942392 - Digital Dance for People With Parkinson's Disease During the COVID-19 Pandemic N/A
Terminated NCT03446833 - LFP Beta aDBS Feasibility Study N/A
Completed NCT03497884 - Individualized Precise Localization of rTMS on Primary Motor Area N/A
Completed NCT05538455 - Investigating ProCare4Life Impact on Quality of Life of Elderly Subjects With Neurodegenerative Diseases N/A
Recruiting NCT04997642 - Parkinson's Disease and Movement Disorders Clinical Database
Completed NCT04117737 - A Pilot Study of Virtual Reality and Antigravity Treadmill for Gait Improvement in Parkinson N/A